RxDoctor Payments Data

John McCabe, MD

Cardiovascular Disease · Winston Salem, NCNPI 1598723660

Payments from drug & device makers

$3,867in general payments, 2019–2025

Across 216 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$893
  • AstraZeneca$544
  • Abiomed$445
  • E.r. Squibb & Sons, L.L.C.$357
  • Amgen$302
  • Johnson & Johnson$284
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,71296%
  • Education$1544%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,867 in reported general payments places this provider in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$90,393
Medicare patients
420
Services billed
1,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban607$571,137
XareltoRivaroxaban150$158,592
AdempasRiociguat12$155,977
EntrestoSacubitril/Valsartan124$124,712
JardianceEmpagliflozin39$41,134
Repatha SureclickEvolocumab60$33,854
BrilintaTicagrelor23$20,925
FarxigaDapagliflozin Propanediol25$18,116
MultaqDronedarone Hcl21$16,167
Metoprolol Succinate590$7,052
Ranolazine ErRanolazine71$4,998
Carvedilol ErCarvedilol Phosphate13$4,898
Diltiazem 12hr ErDiltiazem Hcl27$4,825
Propafenone Hcl ErPropafenone Hcl11$4,352
Rosuvastatin Calcium407$3,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$571,137607 claims
Johnson & JohnsonXarelto$284$158,592150 claims
BayerAdempas$15$155,97712 claims
NovartisEntresto$893$124,712124 claims
Boehringer IngelheimJardiance$133$41,13439 claims
AstraZenecaBrilinta, Farxiga$544$39,04048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →